Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Liabilities and Shareholders Equity: 2015-2020

Historic Liabilities and Shareholders Equity for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $30.2 million.

  • Outlook Therapeutics' Liabilities and Shareholders Equity fell 8.95% to $30.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was $71.0 million, marking a year-over-year decrease of 22.33%. This contributed to the annual value of $17.1 million for FY2019, which is 23.10% down from last year.
  • Outlook Therapeutics' Liabilities and Shareholders Equity amounted to $30.2 million in Q2 2020, which was up 129.64% from $13.2 million recorded in Q1 2020.
  • Outlook Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $34.1 million for Q2 2018, and its period low was $10.4 million during Q4 2019.
  • For the 3-year period, Outlook Therapeutics' Liabilities and Shareholders Equity averaged around $22.4 million, with its median value being $20.5 million (2018).
  • As far as peak fluctuations go, Outlook Therapeutics' Liabilities and Shareholders Equity tumbled by 48.09% in 2017, and later spiked by 99.02% in 2018.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Liabilities and Shareholders Equity stood at $20.4 million in 2016, then spiked by 57.86% to $32.3 million in 2017, then tumbled by 42.03% to $18.7 million in 2018, then crashed by 44.29% to $10.4 million in 2019, then fell by 8.95% to $30.2 million in 2020.
  • Its last three reported values are $30.2 million in Q2 2020, $13.2 million for Q1 2020, and $10.4 million during Q4 2019.